Treating Blood Cancers

Matthew Kutny, MD, University of Alabama, Birmingham, AL, Julie Guillot, Pediatric AML parent, global advocate, and Blood Cancer United Volunteer, and Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC

Recorded on February 19, 2026

Matthew Kutny, MD

Professor of Pediatrics

Director, Leukemia, Lymphoma and Histiocytosis Program

Director, Pediatric Clinical Trials Office

Institutional Principal Investigator, Children’s Oncology Group (NCI NCTN)

Pediatric Hematology and Oncology

University of Alabama at Birmingham

Birmingham, AL

Julie Guillot

Pediatric AML parent, global advocate, and Blood Cancer United Volunteer

Kelly Laschinger, MSN, RN, CPNP, CPHON

Director, Clinical Trial Support Center

Blood Cancer United

Washington, DC

In this episode, Dr. Matthew Kutny from the University of Alabama, and Kelly Laschinger, CPNP and Julie Guillot from Blood Cancer United, break down what clinicians and families need to know about Expanded Access (EA), also known as Compassionate Use, in treating pediatric oncology patients. They clarify key terms, outline when EA should be considered, and walk through how the process works in real-world practice. Their conversation also addresses common barriers, from institutional requirements to sponsor approval, and highlights how pediatric care teams and advocates can work together to navigate them. Tune in for an informative and insightful conversation to help healthcare professionals better understand and utilize Expanded Access!

Blood Cancer United Resources:

Clinical Trial Support Center

Information Resource Center

Dare to Dream Project

Pediatric Acute Leukemia Master Clinical Trial (PedAL)

Mentioned on this episode:

Project Facilitate

This episode is supported by the Tom Reich Educational Endowment Fund.

Brad Kahl, MD, Siteman Cancer Center, St. Louis MO

Recorded on January 27, 2026

Brad Kahl, MD

Professor of Medicine

Division of Oncology, Department of Medicine

Washington University School of Medicine

Director, Lymphoma Program

Siteman Cancer Center

St. Louis, MO

In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion!

Additional Blood Cancer United Resources:

Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education

Blood Cancer United Resources for Patients

Pam Simon, MSN, CPNP, CPON, Stanford Adolescent and Young Adult Cancer Program (SAYAC), Palo Alto, CA and H. Irene Su, MD MSCE, University of California San Diego, San Diego, CA

Recorded on January 20, 2026

Pam Simon, MSN, CPNP, CPON

Nurse Practitioner & Program Manager

Stanford Adolescent and Young Adult Cancer Program (SAYAC)

Palo Alto, CA

H. Irene Su, MD MSCE

Professor

Reproductive Endocrinology and Infertility Fellowship Director

Division of Reproductive Endocrinology and Infertility

Co-Director, Center for Obstetrics and Gynecology Research Innovations

Department of Obstetrics, Gynecology and Reproductive Sciences

Director, Moores Cancer Center Leadership Academy

University of California San Diego

San Diego, CA

In this episode, we’re joined by Dr. Irene Su, Professor of Obstetrics, Gynecology, and Reproductive Sciences at UC San Diego, and Pam Simon, Nurse Practitioner and Program Manager of the Stanford Adolescent and Young Adult (AYA) Cancer Program at Stanford Medicine. They discuss fertility risk across treatment types, approaches to fertility preservation and reproductive survivorship planning, insurance and access considerations, and the cultural and sociodemographic factors that shape care. They also share strategies to support shared decision-making and promote psychosocial well being for AYA patients and survivors. Tune in for practical insights to strengthen your approach to fertility care for AYAs.

Mentioned on this episode:

OncofertilityRisk.com

The Alliance for Fertility Preservation

Additional Blood Cancer United Resources:

Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education

Blood Cancer United Resources for Patients

Chelsey Winegar, LCSW, MBA, Intermountain Health, Murray, UT

Recorded on January 8, 2026

Chelsey Winegar, LCSW, MBA

Manager of Oncology Services

Intermountain Health

Murray, UT

Join Chelsey Winegar, LCSW and Manager of Oncology Services at Intermountain Health in Murray, UT, as she breaks down the key differences between burnout and compassion fatigue, and why understanding both is essential for the well being of healthcare professionals and the patients they serve.
Chelsey shares practical strategies for recognizing early warning signs, monitoring staff wellness, and building supportive, stigma free environments. The episode also highlights resources and education to help clinicians maintain resilience in demanding clinical settings. Listen in to learn more today!

Mentioned on this episode:

Trauma Stewardship

Additional Blood Cancer United Resources:

Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education

Blood Cancer United Resources for Patients

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC

Recorded on December 18, 2025

Lore Gruenbaum, PhD

Chief Scientific Officer & Senior Vice President of Research

Blood Cancer United

Washington, DC

Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know!

Additional Blood Cancer United Resources:

Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education

Blood Cancer United Resources for Patients